Trial of Iressa in Prostate Cancer Patients

An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy

This study is being carried out to see if ZD1839 is effective in treating prostate cancer after being diagnosed with an early rising PSA (prostate specific antigen) following surgery.

Inclusion Criteria:

• Removal of prostate for prostate cancer
• Raised level of prostate specific antigen (PSA) post-surgery
• Can have received some radiation therapy

Exclusion Criteria:

• Any after surgery male hormone blocking therapy.
• Low white blood cell count
• Abnormal liver function test